BioSpace News Archive

ASC Therapeutics, A Division of Applied StemCell, Inc., announced that it has obtained an exclusive therapeutics license from Expression Therapeutics, LLC for coagulation factor VIII expression technologies including a highly compact, yet potent, liver-directed promoter and matching liver-codon optimized factor VIII transgene for adeno-associated viral vector gene therapy of hemophilia A.

The combination of more readily available health data of all kinds combined with the rapid proliferation of machine learning/artificial intelligence techniques has created an ecosystem with immense opportunities to shape patient outcomes.

GRYT Health today announced the formation of its advisory board to provide strategic counsel as the Company continues to execute its business strategy.

Announces resignation of Chief Medical Officer effective August 31, 2019

Parvus Eligible to Receive Upfront and Milestone Payments Exceeding $800 Million Plus Royalties on Net Sales